¡Ya estamos en ! Descubre más

Glaukos

GKOS

Capitalización de mercado USD 9723 M

164.84 USD

-0.76

0.46%

Al cierre Actualizado 16 oct, 4:00 p.m. EDT

Antes de la apertura del mercado

Después del cierre del mercado

164.84

0.00

0%

1 día

-0.46%

5 días

-1.17%

1 mes

0.84%

3 meses

6.08%

6 meses

35.54%

En lo que va del año

48.88%

1 año

93.18%

5 años

263.32%

10 años

364.34%

Acerca de: Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Empleados: 1,094

Atención médica Dispositivos médicos

Noticias

Positivo

Neutral

Negativo

Sentimiento 3 meses

Positivo 54.2%

Neutral 41.7%

Negativo 4.2%

Zacks Investment Research

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.

Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?

Glaukos: The Second J-Code Rewrites The Risk Math

Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharmaceutical platform with two J-coded drugs and strong operating leverage. Q2 net sales grew 50% YoY to $185.6M, driven by iDose TR and the Epioxa launch, with non-GAAP gross margin reaching 85% and breakeven P&L. Management raised 2026 net sales guidance to $680–700M, with iDose TR sales expected at $275–280M and corneal health growth of 20%+.

Glaukos: The Second J-Code Rewrites The Risk Math

Zacks Investment Research

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.

Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported successful topline outcomes from its latest Phase 4 clinical study.

Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunction with cataract surgery compared to cataract surgery alone in patients with open-angle glaucoma (OA.

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal

Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus treatment while simultaneously securing an exclusive licensing deal to broaden its pipeline of retinal disease therapies.

Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and commercialize RO-104, a novel tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macula edema (DME), diabetic retinopat.

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases

Glaukos says late-stage eye disease treatment shows lasting benefits after single dose

Glaukos said on Wednesday patients treated with its late-stage eye disease therapy maintained improvements in vision and corneal shape three years ‌after a single treatment for keratoconus, a disease that can progressively distort vision.

Glaukos says late-stage eye disease treatment shows lasting benefits after single dose

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating the durability, visual outcomes, and safety of Epioxa®, the company's groundbreaking epi-on corneal cross-linking therapy for the treatment of keratoconus, a sigh.

Glaukos Announces Positive Three-Year Epioxa® Results Demonstrating Durable Clinical Outcomes in Keratoconus

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release third quarter 2026 financial results after the market close on Wednesday, October 28, 2026. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on October 28, 2026. A link.

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28

Ver rankings de noticias

Gráficos de precios implementados con Lightweight Charts™